Whats more, its connected with a high threat of negative effects, especially diarrhea, the analysis shows.
Early observational studies suggested that colchicine may be a beneficial addition to the treatments available for COVID-19 infection, and it has already found its method into clinical practice in some locations.
In a bid to clarify its security and effectiveness, the researchers trawled research databases searching for pertinent relative clinical trial information on using the drug for the treatment of COVID-19 infection, published approximately July 2021.
The scientists desired to discover if colchicine lowered the risk of death, the need for ventilatory support, extensive care admission, and length of hospital stay; and if its usage was related to any specific side effects..
They applied the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) technique to examine the quality of the evidence for each of these results.
Observational studies, laboratory research studies, animal studies, and studies with less than 10 participants were all excluded.
Out of 69 complete texts evaluated, 6 randomized controlled trials involving 16,148 clients with differing degrees of seriousness of COVID-19 were included in the pooled data analysis..
This revealed that there was no substantial decrease in the danger of death (6 studies), the requirement for ventilatory assistance (5 research studies), admission to extensive care (3 studies), length of health center stay (4 research studies) or major negative effects (3 studies) in between those clients treated with colchicine and those offered usual encouraging care just..
Clients taking colchicine also had 58% greater rates of negative effects and almost double the danger of diarrhea than those provided helpful care..
The GRADE quality of the proof was moderate for most of the results studied.
The scientists care: “Our findings on colchicine must be analyzed meticulously due to the inclusion of open labeled randomized clinical trials. The analysis of efficacy and safety outcomes are based on a small number of [randomized controlled trials] in control interventions.”.
They conclude: “Colchicine does not decrease the danger of mortality, need for ventilatory support, intensive care system admission or length of hospital stay among clients with COVID-19. There is no fringe benefit of including colchicine to encouraging care in the management of patients with COVID-19.”.
Referral: “Efficacy and security of colchicine in COVID-19: a meta-analysis of randomised controlled trials” 22 November 2021, RMD Open.DOI: 10.1136/ rmdopen-2021-001746.
The researchers care: “Our findings on colchicine must be interpreted meticulously due to the inclusion of open labeled randomized clinical trials.
Nor does it cut hospital stay and is connected with high side impact threat.
Colchicine, a low-cost anti-inflammatory drug typically utilized to deal with gout, doesnt minimize COVID-19 severity or fend off the threat of death from the infection in healthcare facility clients, discovers a pooled analysis of the offered evidence, published outdoors gain access to journal RMD Open.
